• Live - Live breaking news
  • Covid-19: coronavirus symptoms, treatment and how to avoid contagion
  • Recommendations: is it allergy or coronavirus? These are the keys to differentiate the symptoms

The World Health Organization continues to fuel the controversy and give arguments to the voices that point it out as a pro-China body with a mediocre role in what is being the greatest health crisis that Humanity has experienced in recent centuries. The WHO itself has mistakenly published - "accidentally" - draft documents on early clinical trials of a promising coronavirus drug that show poor antiviral results .

In the Chinese trial, researchers studied 237 patients. Of these, they administered the medication from the pharmaceutical company Gilead Sciences - called Remdesivir - to 158 and compared their progress with the remaining 79. According to leaked drafts, the drug did not improve the disease in patients or reduce the presence of the pathogen in their bloodstream. Furthermore, according to the document advanced by the Financial Times , the antiviral also showed significant side effects in some of the patients , which resulted in 18 of them having to abandon the trial.

Interest in the Gilead drug had been very high, as there are currently no approved treatments or preventive vaccines against Covid-19, and doctors are eager to find any drugs that can alter the course of the disease. Perhaps for this reason, the shares of the North American company have appreciated more than 25% since the beginning of the year, from the little more than 65 dollars that marked in early 2020 to almost 84 dollars today. Only during the stock market bleeding has it gained 17% . However, in the last hours the titles have fallen around 6%.

Remdesivir, is an ativiral that previously failed as a treatment for Ebola. It has been tested for weeks against the coronavirus because it is designed to disable the mechanism by which certain viruses, including the new SARS-CoV-2, make copies of themselves and potentially overwhelm the body's immune system.

The company's position

The American company has criticized the World Health Organization for such accidental publication and assure that the study carried out in China was not of sufficient quality to be treated as a quality clinical trial.

"We regret that the WHO has prematurely published information about the study, which has already been deleted. The researchers in this study did not give permission for the publication of results. In addition, we believe that the publication includes an inappropriate description of the study. It is important to note that This study ended prematurely due to low patient recruitment and therefore does not have the necessary robustness to obtain statistically significant conclusions. Therefore, the results of the study are not conclusive, although the data suggests a potential benefit for remdesivir, particularly among those patients who were treated in the early stages of the disease. We understand that the available data has been submitted for publication in a peer-reviewed scientific publication, which will provide more detailed information on this study in the near future, " ensures the pharmacist in a statement.

"There are several ongoing phase 3 studies that are designed to provide the additional data needed to determine the potential of remdesivir as a treatment for Covid-19. These studies will provide more information on who to treat, when to treat, and how long to treat with remdesivir . Studies have already completed recruitment for the primary analysis or are on track to do so in the short term, "they explain from Gilead.

According to the criteria of The Trust Project

Know more

  • Coronavirus
  • Covid 19
  • Science and health

Covid-19Spanish excavations in Egypt quarantined by coronavirus

Covid-19Spanish healthcare 'loses' almost 5,000 professionals in March

Health WHO calls on young people to call once a day for elderly and sick people confined by the coronavirus